Laura M Mann1, Eloisa Llata1, Elaine W Flagg1, Jaeyoung Hong1, Lenore Asbel2, Juli Carlos-Henderson3, Roxanne P Kerani4, Robert Kohn5, Preeti Pathela6, Christina Schumacher7, Elizabeth A Torrone1. 1. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB, Centers for Disease Control and Prevention, Atlanta, GA. 2. City of Philadelphia Department of Public Health, Pennsylvania. 3. County of Los Angeles Department of Public Health, California. 4. Seattle and King County Public Health, Washington. 5. San Francisco Department of Public Health, California. 6. New York City Department of Health and Mental Hygiene, New York. 7. Baltimore City Health Department, Maryland.
Abstract
BACKGROUND: Approximately 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11. In the United States, HPV vaccination has been recommended for girls and women aged ≤26 years, and since 2011, for boys and men aged ≤21 years and for gay, bisexual, and other men who have sex with men (MSM) aged ≤26 years. METHODS: Data were obtained from 27 clinics participating in the STD Surveillance Network. Trends in the annual prevalence of anogenital warts (AGW) from 2010-2016 were described by sex and by the sex of sex partners. RESULTS: During 2010-2016, significant declines in the prevalence of AGW were observed in women aged <40 years, men who have sex with women only (MSW) aged <40 years, and MSM of all age categories. An inflection in trend in 2012 was noted for MSW aged 20-24 or 25-29 years and for MSM aged 20-24 years. CONCLUSIONS: The observed declines in the prevalence of AGW suggest that HPV morbidity is declining among populations attending STD clinics, including MSW, MSM, and women. Declines in younger age groups are consistent with what would be expected following the implementation of HPV vaccination. However, declines were also observed in older age groups and are not likely to be the result of vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
BACKGROUND: Approximately 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11. In the United States, HPV vaccination has been recommended for girls and women aged ≤26 years, and since 2011, for boys and men aged ≤21 years and for gay, bisexual, and other men who have sex with men (MSM) aged ≤26 years. METHODS: Data were obtained from 27 clinics participating in the STD Surveillance Network. Trends in the annual prevalence of anogenital warts (AGW) from 2010-2016 were described by sex and by the sex of sex partners. RESULTS: During 2010-2016, significant declines in the prevalence of AGW were observed in women aged <40 years, men who have sex with women only (MSW) aged <40 years, and MSM of all age categories. An inflection in trend in 2012 was noted for MSW aged 20-24 or 25-29 years and for MSM aged 20-24 years. CONCLUSIONS: The observed declines in the prevalence of AGW suggest that HPV morbidity is declining among populations attending STD clinics, including MSW, MSM, and women. Declines in younger age groups are consistent with what would be expected following the implementation of HPV vaccination. However, declines were also observed in older age groups and are not likely to be the result of vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
Authors: Elissa Meites; Eloisa Llata; Susan Hariri; Jonathan Zenilman; Lisa Longfellow; Jane Schwebke; Irina Tabidze; Christie Mettenbrink; Heidi Jenkins; Sarah Guerry; Preeti Pathela; Lenore Asbel; Jeffrey A Stover; Kyle Bernstein; Roxanne P Kerani; Eileen F Dunne; Lauri E Markowitz Journal: Sex Transm Dis Date: 2012-01 Impact factor: 2.830
Authors: Gabriella M Anic; Ji-Hyun Lee; Heather Stockwell; Dana E Rollison; Yougui Wu; Mary R Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Martha Abrahamsen; Anna R Giuliano Journal: J Infect Dis Date: 2011-10-19 Impact factor: 5.226
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: C L Celum; G Bolan; M Krone; K Code; P Leone; C Spaulding; K Henry; P Clarke; M Smith; E W Hook Journal: Sex Transm Dis Date: 1997-11 Impact factor: 2.830
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2007-03-23
Authors: Louise Baandrup; Maria Blomberg; Christian Dehlendorff; Carsten Sand; Klaus K Andersen; Susanne K Kjaer Journal: Sex Transm Dis Date: 2013-02 Impact factor: 2.830
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: L Gissmann; L Wolnik; H Ikenberg; U Koldovsky; H G Schnürch; H zur Hausen Journal: Proc Natl Acad Sci U S A Date: 1983-01 Impact factor: 11.205
Authors: Arnaud John Kombe Kombe; Bofeng Li; Ayesha Zahid; Hylemariam Mihiretie Mengist; Guy-Armel Bounda; Ying Zhou; Tengchuan Jin Journal: Front Public Health Date: 2021-01-20
Authors: Anita Lukács; Zsuzsanna Máté; Nelli Farkas; Alexandra Mikó; Judit Tenk; Péter Hegyi; Balázs Németh; László Márk Czumbel; Sadaeng Wuttapon; István Kiss; Zoltán Gyöngyi; Gábor Varga; Zoltán Rumbus; Andrea Szabó Journal: BMC Public Health Date: 2020-05-28 Impact factor: 3.295